title: 68Ga-DOTA-peptides in the diagnosis of NET.
abstract: (68)Ga-DOTA-peptides are increasingly used for the detection of neuroendocrine tumors (NET) in clinical trials in Europe. They have been proved accurate for the detection of NET lesions (at primary and metastatic sites) and no adverse effects were recorded. Moreover, providing data on somatostatin receptors expression on NET cells, (68)Ga-DOTA-peptides PET/CT is becoming a fundamental procedure to be performed before starting therapy and to guide treatment with either hot or cold somatostatin analogues. The easy and economic synthesis process is another advantage that is supporting its clinical use even in centers without an on-site cyclotron.
authors.affiliation: Nuclear Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Via Massarenti 9, Bologna 40138, Italy. Electronic address: valentina.ambrosini@aosp.bo.it.
authors.forename: Valentina
authors.initials: V
authors.lastname: Ambrosini
authors.affiliation: Nuclear Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Via Massarenti 9, Bologna 40138, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Fanti
mesh_terms: D006801:Humans; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging*; D015282:Octreotide / Q000031:analogs & derivatives*; D009942:Organometallic Compounds; D049268:Positron-Emission Tomography / Q000379:methods* / Q000592:standards; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity
chemical_list: C499142:Ga(III)-DOTATOC; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D015282:Octreotide
keywords: (68)Ga-DOTA-peptides; Neuroendocrine tumors; PET/CT; Somatostatin receptors